Copyright
©The Author(s) 2017.
World J Gastroenterol. Feb 14, 2017; 23(6): 1090-1097
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1090
Published online Feb 14, 2017. doi: 10.3748/wjg.v23.i6.1090
Table 2 Hematologic and non-hematologic adverse events n (%)
Any grade | Grade 3 | Grade 4 | |
Leukopenia | 7 (87.5) | 2 (25) | 0 |
Neutropenia | 7 (87.5) | 4 (50) | 2 (25) |
Anemia | 6 (75) | 1 (12.5) | 0 |
Thrombocytopenia | 7 (87.5) | 0 | 0 |
Hyperbilirubinemia | 3 (37.5) | 0 | 0 |
Elevated serum aspartate aminotransferase | 6 (75) | 0 | 0 |
Elevated serum alanine aminotransferase | 8 (100) | 0 | 0 |
Elevated serum creatinine | 3 (37.5) | 0 | 0 |
Fever | 4 (50) | 0 | 0 |
Fatigue | 2 (25) | 0 | 0 |
Alopecia | 1 (12.5) | 0 | 0 |
Skin rash | 1 (12.5) | 0 | 0 |
Anorexia | 7 (87.5) | 4 (50) | 0 |
Diarrhea | 4 (50) | 2 (25) | 0 |
Nausea | 3 (37.5) | 0 | 0 |
Vomiting | 3 (37.5) | 0 | 0 |
Constipation | 1 (12.5) | 0 | 0 |
Peripheral neuropathy | 1 (12.5) | 0 | 0 |
Infection | 1 (12.5) | 1 (12.5) | 0 |
- Citation: Maeda O, Matsuoka A, Miyahara R, Funasaka K, Hirooka Y, Fukaya M, Nagino M, Kodera Y, Goto H, Ando Y. Modified docetaxel, cisplatin and capecitabine for stage IV gastric cancer in Japanese patients: A feasibility study. World J Gastroenterol 2017; 23(6): 1090-1097
- URL: https://www.wjgnet.com/1007-9327/full/v23/i6/1090.htm
- DOI: https://dx.doi.org/10.3748/wjg.v23.i6.1090